Navigation Links
FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
Date:3/26/2008

BALTIMORE, March 26 /PRNewswire/ -- FASgen Diagnostics, LLC is pleased to report that results of studies using the Company's FAS-detect(TM) IHC and FAS- detect(TM) ELISA research tests were the subject of an address to Society of Gynecologic Oncologists annual meeting last week in Tampa, Florida. The report, "Over-expression of Fatty Acid Synthase (FAS) in Recurrent Ovarian Serous Carcinomas and its Potential Diagnostic and Therapeutic Role in Chemoresistant Disease," presented the data from studies conducted at the Johns Hopkins Oncology Center in cooperation with the Norwegian Radium Hospital.

The FAS-detect(TM) IHC test was used in evaluating 321 samples of serous ovarian cancer. FAS expression correlated with high grade disease and was an independent prognostic indicator. Patients with high levels of FAS expression survived for 36.9 months compared to 60.4 months for low expressors. Furthermore, FAS levels were highest in recurrent tumors. This is similar to prior findings in prostate and breast cancer. The FAS-detect(TM) ELISA was used to measure FAS levels in ovarian cancer ascites in 117 advanced stage serous carcinomas and 58 non-malignant controls, producing median results of 46.3 ng/ml of FAS in the ovarian cancer samples and 1.3 ng/ml in the controls.

The report further identifies the apoptotic effect of several FASi compounds from FASgen, Inc., an affiliated company of FASgen Diagnostics, LLC, which makes FASi compounds intended for therapeutic use in treating cancer. The results for FASgen's C-93 demonstrated significant apoptosis in SKOV3 and A2780 cell lines, i.e., > 70% within 48 hours. Similar findings were obtained with Taxol and Carboplatin resistant cell lines indicating that FAS inhibitors produce significant apoptosis to overcome hypoxia-induced chemoresistance. These in vitro data confirm the extensive xenograft results in ovarian, lung and colon cancers previously announced by FASgen. FAS is thus a promising target for chemoresistant and recurrent ovarian cancer.

About FASgen Diagnostics, LLC and FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

FASgen Diagnostics, LLC, an affiliated company, is a diagnostic company producing research tests for measuring the over expression of FAS in cancer. FAS-detect(TM) IHC and FAS-detect(TM) ELISA are marketed for research purposes.

FASgen has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com


'/>"/>
SOURCE FASgen Diagnostics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FASgen Announces New Research Discoveries in Lung Cancer
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
5. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
6. Hypertension Diagnostics Announces Fiscal Year 2007 Results
7. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
8. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
9. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
10. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
11. New peritoneal dialysis diagnostic discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... Forum which featured keynote addresses by Donald W. Rucker, MD, head of the ...
(Date:8/23/2017)... ... ... Nightingale College continues the semiannual Give Back Day tradition for its fourth year ... serving and volunteering for organizations that provide indispensable resources to the community. The College ... little extra help. , The College’s Give Back Day initiative began in 2013 ...
(Date:8/23/2017)... Elkhart, Indiana (PRWEB) , ... August 23, 2017 ... ... Whitney Boling, MD , has returned home to Indiana, and is now ... Boling is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC ... Awards® - for Risk Management Solution Innovations and Security Solution for Government Innovations. ... released in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , ...
(Date:8/22/2017)... ... 22, 2017 , ... The Women’s Choice Award, a growing platform that gives ... 2017 Women’s Choice Award. The identification by women of an effective new migraine ... sufferers are women. In a survey taken by the Women’s Choice Award organization, nine ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Law and Gulf Coast Regional Blood Center to host a ... Mostyn Law family has had 3 members that needed blood ... Law is partnering with Gulf Coast Regional Blood Center of ... Blood supplies are running low. Gulf Coast Regional Blood Center,s inventory ... That is why the blood center reached out to Mostyn ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
Breaking Medicine Technology: